Bedaquiline

Brand names: Sirturo · Active ingredient: Bedaquiline Fumarate

In short: SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid

Forms & strengthsSIRTURO 20 mg tablet: uncoated, white to almost white oblong functionally scored tablet, with a score line on both sides, debossed with "2" and "0" on one side and plain on the other side. …
LabelJanssen Products, LP
Label updatedNov 17, 2025

What is Bedaquiline used for?

SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to

Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.

Limitations of Use

Do not use SIRTURO for the treatment of:

Latent infection due to

Mycobacterium tuberculosis (

M. tuberculosis)

Drug-sensitive pulmonary TB

Extra-pulmonary TB

Infections caused by non-tuberculous mycobacteria

âš  Boxed warning (FDA's strongest warning)

QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops

.

Bedaquiline dosage

Administer SIRTURO by directly observed therapy (DOT).

Only use SIRTURO in combination with at least three other drugs to which the patient's TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, SIRTURO treatment may be initiated in combination with at least four other drugs to which the patient's TB isolate is likely to be susceptible. Refer to the prescribing information of the drugs used in combination with SIRTURO for further information.

SIRTURO (20 mg and 100 mg) must be taken with food.

SIRTURO 20 mg are functionally scored tablets which can be split at the scored lines into two equal halves of 10 mg each to provide doses less than 20 mg

.

As an alternative method of administration, SIRTURO 20 mg tablets can be dispersed in water and administered or dispersed in water and further mixed with a beverage or soft food, or crushed and mixed with soft food, or administered through a feeding tube

.

Emphasize the need for compliance with the full course of therapy.

Prior to treatment with SIRTURO, obtain the following:

Susceptibility information for the background regimen against

M. tuberculosis isolate if possible

ECG

Serum potassium, calcium, and magnesium concentrations

Liver enzymes

The recommended dosage of SIRTURO in adult patients is:

Dosage Recommendation

Weeks 1 and 2 | Weeks 3 to 24

At least 48 hours between doses

400 mg (4 of the 100 mg tablets OR 20 of the 20 mg tablets) orally

once daily | 200 mg (2 of the 100 mg tablets OR 10 of the 20 mg tablets) orally

three times per week

Recommended dosage in pediatric patients is described in Table 2 below

.

Administer SIRTURO tablets with food. The total duration of treatment with SIRTURO in adults is 24 weeks. When treatment with SIRTURO is considered necessary beyond 24 weeks, treatment may be continued at a dose of 200 mg three times per week

. …

How to take Bedaquiline — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Medication Guide).

Serious Adverse Reactions

Advise patients that the following serious side effects can occur with SIRTURO: heart rhythm abnormalities, death and/or hepatitis. In addition, advise patients about other potential side effects: nausea, vomiting, joint pain, increased transaminases, dizziness, headache, myalgia, diarrhea, increased blood amylase, hemoptysis, chest pain, anorexia, rash, and/or abdominal pain. Additional testing may be needed to monitor or reduce the likelihood of adverse effects.

Compliance with Treatment

Advise patients to take SIRTURO in combination with other antimycobacterial drugs as prescribed. Emphasize compliance with the full course of therapy. Advise patients that skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the treatment and (2) increase the likelihood that their mycobacterium may develop resistance and the disease will not be treatable by SIRTURO or other antimycobacterial drugs in the future. …

Warnings & precautions

Do not take this medicine if: None.

SIRTURO prolongs the QTc interval

. Use with drugs that prolong the QTc interval may cause additive QTc prolongation

. In Study 4, where SIRTURO was administered with the QTc prolonging drugs clofazimine and levofloxacin, 5% of patients in the 40-week SIRTURO treatment group experienced a QTc ≥500 ms and 43% of patients experienced an increase in QTc ≥60 ms over baseline. Of the clofazimine- and levofloxacin-treated patients in the 40-week control arm, 7% of patients experienced a QTc ≥500 ms and 39% experienced an increase in QTc ≥60 ms over baseline.

Obtain an ECG before initiation of treatment, 2 weeks after initiation, during treatment, as clinically indicated and at the expected time of maximum increase in the QTc interval of the concomitantly administered QTc prolonging drugs (as applicable). Obtain electrolytes at baseline and during treatment and correct electrolytes as clinically indicated.

The following may increase the risk for QTc prolongation when patients are taking SIRTURO:

use with other QTc prolonging drugs

a history of Torsade de Pointes

a history of congenital long QTc syndrome

a history of or ongoing hypothyroidism

a history of or ongoing bradyarrhythmias

a history of uncompensated heart failure

serum calcium, magnesium, or potassium levels below the lower limits of normal

Discontinue SIRTURO if the patient develops:

Clinically significant ventricular arrhythmia

A QTc interval of greater than 500 ms (confirmed by repeat ECG)

If syncope occurs, obtain an ECG to detect QTc prolongation.

An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial in adults (Study 1; based on the 120 week visit window). One death occurred during the 24 weeks of administration of SIRTURO. The imbalance in deaths is unexplained. …

Bedaquiline side effects

The following serious adverse reactions are discussed elsewhere in the labeling:

QTc Prolongation

Mortality Imbalance in Clinical Trials

Hepatotoxicity

Drug Interactions

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. Refer to the prescribing information of the drugs used in combination with SIRTURO for their respective adverse reactions.

Clinical Studies Experience in Adults

Adverse reactions for SIRTURO were identified from safety data from 335 patients who received SIRTURO for eight weeks (Study 2) and 24 weeks (Studies 1 and 3), and 354 patients who received SIRTURO for 40 weeks or 28 weeks (Study 4). In these studies, patients received SIRTURO in combination with other antimycobacterial drugs.

Studies 1 and 2 were randomized, double-blind, placebo-controlled trials in newly diagnosed patients with pulmonary TB due to

M. tuberculosis resistant to at least rifampin and isoniazid. Study 3 was an open-label, noncomparative study with SIRTURO administered as part of an individualized treatment regimen in previously treated patients with pulmonary TB due to

M. tuberculosis resistant to at least rifampin and isoniazid, including patients resistant to second-line injectables and/or fluroquinolones. …

Drug interactions

Strong and Moderate CYP3A4 Inducers

Coadministration of SIRTURO with moderate or strong CYP3A4 inducers may decrease systemic exposure of bedaquiline. Avoid coadministration of SIRTURO with strong or moderate CYP3A4 inducers

.

CYP3A4 Inhibitors

Coadministration of SIRTURO with CYP3A4 inhibitors increases the systemic exposure of bedaquiline which may increase the risk of adverse reactions. Closely monitor patient safety (e.g., liver function) when SIRTURO is coadministered with CYP3A4 inhibitors. No dose adjustment of SIRTURO is needed when coadministered with CYP3A4 inhibitors

.

No dose adjustment of isoniazid or pyrazinamide is required during coadministration with SIRTURO.

In a placebo-controlled clinical trial in adult patients, no major impact of coadministration of SIRTURO on the pharmacokinetics of ethambutol, kanamycin, pyrazinamide, ofloxacin or cycloserine was observed.

In clinical trials of adult patients, additional QTc interval prolongation was observed during combination treatment with SIRTURO and other QTc prolonging drugs. …

About this medicine

SIRTURO

® contains bedaquiline fumarate, a diarylquinoline antimycobacterial drug for oral administration. Each SIRTURO 20 mg tablet contains 20 mg of bedaquiline (equivalent to 24.18 mg of bedaquiline fumarate). Each SIRTURO 100 mg tablet contains 100 mg of bedaquiline (equivalent to 120.89 mg of bedaquiline fumarate).

Bedaquiline fumarate is a white to almost white powder and is practically insoluble in aqueous media. The chemical name of bedaquiline fumarate is (1

R, 2

S)-1-(6-bromo-2-methoxy-3-quinolinyl)-4-(dimethylamino)-2-(1-naphthalenyl)-1-phenyl-2-butanol compound with fumaric acid (1:1). It has a molecular formula of C

32H

31BrN

2O

2∙C

4H

4O

4 and a molecular weight of 671.58 (555.50 + 116.07). The molecular structure of bedaquiline fumarate is the following:

SIRTURO 20 mg tablet contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose 2910 5 mPa.s, polysorbate 20, purified water (removed during processing), silicified microcrystalline cellulose and sodium stearyl fumarate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1534c9ae-4948-4cf4-9f66-222a99db6d0e. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin